We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00760045
First Posted: September 25, 2008
Last Update Posted: January 6, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Alcon Research
  Purpose
The purpose of the study is to observe lacrimal fluid condition (tear film break-up time) chronologically after a single dose of AL-43546 ophthalmic products(0.15%, 0.25% and vehicle)and 0.1% sodium hyaluronate ophthalmic solution and compare lacrimal fluid retention time between them.

Condition Intervention Phase
Dry Eye Disease Drug: Hydroxypropyl Guar Galactomannan Drug: 0.1% sodium hyaluronate ophthalmic solution Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • The change from baseline of non-invasive tear film break up time (ΔNIBUT: seconds). [ Time Frame: Up to 180 minutes ]

Secondary Outcome Measures:
  • Ocular comfort [ Time Frame: After installation ]

Estimated Enrollment: 40
Study Start Date: August 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AL-43546 0.15%
Drug: Hydroxypropyl Guar Galactomannan
One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Experimental: 2
AL-43546 0.25%
Drug: Hydroxypropyl Guar Galactomannan
One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Active Comparator: 3
AL-43546 0%(Vehicle)
Drug: Hydroxypropyl Guar Galactomannan
One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Active Comparator: 4
0.1% sodium hyaluronate ophthalmic solutio
Drug: 0.1% sodium hyaluronate ophthalmic solution
One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects with NIBUT of either eye is 8 seconds or less and other eye is 10 seconds or less at screening test and NIBUT of either eye before instillation in Period I is 10 seconds or less.

Exclusion Criteria:

  • Diagnosis of severe Sjogren's syndrome (history of the use of punctal plug one time or more, etc.) in either eye.
  • Subjects who will use ophthalmic solutions (excluding the specified artificial tear) or ophthalmic ointment in either eye during the study period.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00760045


Locations
Japan
Osaka Pharmacology Clinical Research Hospital
Osaka, Japan, 532-0003
Sponsors and Collaborators
Alcon Research
  More Information

Responsible Party: Koji Hasegawa, Alcon
ClinicalTrials.gov Identifier: NCT00760045     History of Changes
Other Study ID Numbers: C-07-54
First Submitted: September 24, 2008
First Posted: September 25, 2008
Last Update Posted: January 6, 2010
Last Verified: January 2010

Additional relevant MeSH terms:
Eye Diseases
Ophthalmic Solutions
Hyaluronic Acid
Pharmaceutical Solutions
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents